Skip to main content
SpringerLink
Log in

Nutraceuticals in the Management of Osteoarthritis

A Critical Review

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Osteoarthritis (OA) is a chronic, highly prevalent and disabling disease that is expected to increase in prevalence secondary to longer life expectancy and a disproportionately aging population. Treatment of OA is only marginally effective and has been focused primarily on symptom control using weight loss, physical therapy, nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, intra-articular steroids or viscosupplementation, topical NSAIDs and analgesics, diacerein (an oral interleukin-1β inhibitor) and finally joint replacement surgery. The use of nutraceuticals in the treatment of OA is common, and scientific studies examining the effects of nutraceuticals on the pathogenesis and treatment of OA are increasing. This review examines the efficacy and safety of select nutraceuticals for the treatment of OA. The reviewed nutraceuticals include glucosamine, chondroitin, collagen hydrolysates (CHs) and avocado-soybean unsaponifiables (ASUs). There have been several clinical trials examining the efficacy of these products and the results demonstrate significant heterogeneity. Significant improvements in pain, function and structural outcomes have been shown for some of the treatment arms or subgroups of patients, but the effects are not consistent across the studies. Glucosamine, chondroitin and the two in combination have been the most extensively studied. Significant improvement in pain and functional indices and a decrease in the loss of joint space width were demonstrated in some but not all studies. CHs showed significant improvement in pain and functional indices for several subgroups of patients, but these findings were not pervasive amongst the treatment arms. ASU has demonstrated positive results with respect to decreased NSAID use in several studies and functional and pain end points in most of the reviewed studies; however, in the two studies examining structural end points, the results were mixed. The safety of these nutraceuticals has been demonstrated across all of the reviewed trials, and there were no significant issues with tolerance. Given the good safety profile of nutraceuticals, the marginal efficacy of conventional treatments, the high prevalence and rate of disability from OA and the possible benefit of nutraceuticals to patients with OA, use of nutraceuticals in select patients is appropriate. An overall recommendation to use nutraceuticals in the treatment of all patients with OA is not strongly supported by the available data. Future studies should focus on standardization of symptomatic and structural outcome measures, be of longer duration and pay careful attention to the content of the investigational product.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ. 2003;81(9):646–56.

    PubMed  Google Scholar 

  2. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part II. Arthritis Rheum. 2008;58(1):26–35.

    Article  PubMed  Google Scholar 

  3. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part I. Arthritis Rheum. 2008;58(1):15–25.

    Article  PubMed  Google Scholar 

  4. Kotlarz H, Gunnarsson CL, Fang H, et al. Insurer and out-of-pocket costs of osteoarthritis in the US: evidence from national survey data. Arthritis Rheum. 2009;60(12):3546–53.

    Article  PubMed  Google Scholar 

  5. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 1986;29(8):1039–49.

    Article  PubMed  CAS  Google Scholar 

  6. Altman R, Alarcon G, Appelrouth D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum. 1990;33(11):1601–10.

    Article  PubMed  CAS  Google Scholar 

  7. Altman RD, Block DA, Brandt KD, et al. Osteoarthritis: definitions and criteria (letter). Ann Rheum Dis. 1990;49(3):201.

    Article  PubMed  CAS  Google Scholar 

  8. McGonagle D, Tan AL, Grainger AJ, et al. Heberden’s nodes and what Heberden could not see: the pivotal role of ligaments in the pathogenesis of early nodal osteoarthritis and beyond. Rheumatology (Oxford). 2008;47(9):1278–85.

    Article  CAS  Google Scholar 

  9. Berenbaum F. Osteoarthritis: pathology and pathogenesis. In: Klippel JH, Stone JH, Crofford LJ, White PH, editors. Primer on the rheumatic diseases. 13th ed. New York: Springer Science & Business Media; 2008. p. 229–34.

    Google Scholar 

  10. Henrotin YE, Bruckner P, Pujol JP. The role of reactive oxygen species in homeostasis and degradation of cartilage. Osteoarthr Cartil. 2003;11(10):747–55.

    Article  PubMed  CAS  Google Scholar 

  11. Zhang W, Doherty M, Arden N, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2005;64(5):669–81.

    Article  PubMed  CAS  Google Scholar 

  12. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthr Cartil. 2007;15(9):981–1000.

    Article  PubMed  CAS  Google Scholar 

  13. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthr Cartil. 2008;16(2):137–62.

    Article  PubMed  CAS  Google Scholar 

  14. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000; 43 (9): 1905–15.

    Google Scholar 

  15. Jordan KM, Arden NK, Doherty M, et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62(12):1145–55.

    Article  PubMed  CAS  Google Scholar 

  16. Hochberg M, Altman R, April K, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012;64(4):465–74.

    Article  CAS  Google Scholar 

  17. Fidelix TS, Soares BG, Trevisani VF. Diacerein for osteoarthritis. Cochrane Database Syst Rev 2006; (1): CD005117.

  18. National Research Council. Complementary and alternative medicine in the United States. Washington, DC: The National Academies Press; 2005.

    Google Scholar 

  19. Black C, Clar C, Henderson R, et al. The clinical effectiveness of glucosamine and chondroitin supplements in slowing or arresting progression of osteoarthritis of the knee: a systematic review and economic evaluation. Health Technol Assess. 2009;13(52):1–148.

    PubMed  CAS  Google Scholar 

  20. Jackson CG, Plaas AH, Sandy JD, et al. The human pharmacokinetics of oral ingestion of glucosamine and chondroitin sulfate taken separately or in combination. Osteoarthr Cartil. 2010;18(3):297–302.

    Article  PubMed  CAS  Google Scholar 

  21. Persiani S, Rotini R, Trisolino G, et al. Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose. Osteoarthr Cartil. 2007;15(7):764–72.

    Article  PubMed  CAS  Google Scholar 

  22. Altman RD, Abramson S, Bruyere O, et al. Commentary: osteoarthritis of the knee and glucosamine. Osteoarthr Cartil. 2006;14(10):963–6.

    Article  PubMed  CAS  Google Scholar 

  23. Jerosch J. Effects of glucosamine and chondroitin sulfate on cartilage metabolism in OA: outlook on other nutrient partners especially omega-3 fatty acids. Int J Rheumatol. 2011;2011:969012.

    PubMed  Google Scholar 

  24. Bassleer C, Rovati L, Franchimont P. Stimulation of proteoglycan production by glucosamine sulfate in chondrocytes isolated from human osteoarthritic articular cartilage in vitro. Osteoarthr Cartil. 1998;6(6):427–34.

    Article  PubMed  CAS  Google Scholar 

  25. Wang SX, Laverty S, Dumitriu M, et al. The effects of glucosamine hydrochloride on subchondral bone changes in an animal model of osteoarthritis. Arthritis Rheum. 2007;56(5):1537–48.

    Article  PubMed  CAS  Google Scholar 

  26. Roughley PJ. The structure and function of cartilage proteoglycans. Eur Cell Mater. 2006;12:92–101.

    PubMed  CAS  Google Scholar 

  27. Volpi N. Oral bioavailability of chondroitin sulfate (Condrosulf) and its constituents in healthy male volunteers. Osteoarthr Cartil. 2002;10(10):768–77.

    Article  PubMed  CAS  Google Scholar 

  28. Volpi N. Oral absorption and bioavailability of ichthyic origin chondroitin sulfate in healthy male volunteers. Osteoarthr Cartil. 2003;11(6):433–41.

    Article  PubMed  CAS  Google Scholar 

  29. Miller KL, Clegg DO. Glucosamine and chondroitin sulfate. Rheum Dis Clin North Am. 2011;37(1):103–18.

    Article  PubMed  Google Scholar 

  30. Henrotin Y. Advances in the treatment of osteoarthritis and the role of chondroitin sulfate-a review. Eur Musculoskelet Rev. 2010;5(2):11–7.

    CAS  Google Scholar 

  31. Barnhill JG, Fye CL, Williams DW, et al. Chondroitin product selection for the glucosamine/chondroitin arthritis intervention trial. J Am Pharm Assoc (2003) 2006;46(1):14–24.

    Google Scholar 

  32. Russell AS, Aghazadeh-Habashi A, Jamali F. Active ingredient consistency of commercially available glucosamine sulfate products. J Rheumatol. 2002;29(11):2407–9.

    PubMed  CAS  Google Scholar 

  33. Adebowale A, Cox DS, Liang Z, et al. Analysis of glucosamine and chondroitin sulfate in marketed products and the Caco-2 permability of chondroitin sulfate raw materials. J Am Nutraceut Assoc. 2000;3:37–44.

    Google Scholar 

  34. Vlad SC, LaValley MP, McAlindon TE, et al. Glucosamine for pain in osteoarthritis: why do trial results differ? Arthritis Rheum. 2007;56(7):2267–77.

    Article  PubMed  CAS  Google Scholar 

  35. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006;354(8):795–808.

    Article  PubMed  CAS  Google Scholar 

  36. Noack W, Fischer M, Forster KK, et al. Glucosamine sulfate in osteoarthritis of the knee. Osteoarthr Cartil. 1994;2(1):51–9.

    Article  PubMed  CAS  Google Scholar 

  37. Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001;357(9252):251–6.

    Article  PubMed  CAS  Google Scholar 

  38. Pavelka K, Gatterova J, Olejarova M, et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med. 2002;162(18):2113–23.

    Article  PubMed  CAS  Google Scholar 

  39. Herrero-Beaumont G, Ivorra JA, Del Carmen Trabado M, et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum 2007;56(2):555–67.

  40. McAlindon T, Formica M, LaValley M, et al. Effectiveness of glucosamine for symptoms of knee osteoarthritis: results from an internet-based randomized double-blind controlled trial. Am J Med. 2004;117(9):643–9.

    Article  PubMed  CAS  Google Scholar 

  41. Rozendaal RM, Koes BW, van Osch GJ, et al. Effect of glucosamine sulfate on hip osteoarthritis: a randomized trial. Ann Intern Med. 2008;148(4):268–77.

    Article  PubMed  Google Scholar 

  42. Wilkens P, Scheel IB, Grundnes O, et al. Effect of glucosamine on pain-related disability in patients with chronic low back pain and degenerative lumbar osteoarthritis: a randomized controlled trial. JAMA. 2010;304(1):45–52.

    Article  PubMed  CAS  Google Scholar 

  43. Uebelhart D, Malaise M, Marcolongo R, et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthr Cartil. 2004;12(4):269–76.

    Article  PubMed  Google Scholar 

  44. Mazieres B, Combe B, Van Phan A, et al. Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study. J Rheumatol. 2001;28(1):173–81.

    PubMed  CAS  Google Scholar 

  45. Uebelhart D, Thonar EJ, Delmas PD, et al. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthr Cartil 1998;6 Suppl. A:39–46.

    Google Scholar 

  46. Wildi LM, Raynauld JP, Martel-Pelletier J, et al. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI. Ann Rheum Dis. 2011;70(6):982–9.

    Article  PubMed  Google Scholar 

  47. Gabay C, Medinger-Sadowski C, Gascon D, et al. Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial at a single center. Arthritis Rheum. 2011;63(11):3383–91.

    Article  PubMed  CAS  Google Scholar 

  48. Kahan A, Uebelhart D, De Vathaire F, et al. Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2009;60(2):524–33.

    Article  PubMed  CAS  Google Scholar 

  49. Michel BA, Stucki G, Frey D, et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum. 2005;52(3):779–86.

    Article  PubMed  CAS  Google Scholar 

  50. Mazieres B, Hucher M, Zaim M, et al. Effect of chondroitin sulphate in symptomatic knee osteoarthritis: a multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2007;66(5):639–45.

    Article  PubMed  CAS  Google Scholar 

  51. Sawitzke AD, Shi H, Finco MF, et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial. Arthritis Rheum. 2008;58(10):3183–91.

    Article  PubMed  CAS  Google Scholar 

  52. Sawitzke AD, Shi H, Finco MF, et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. Ann Rheum Dis. 2010;69(8):1459–64.

    Article  PubMed  CAS  Google Scholar 

  53. Moskowitz RW. Role of collagen hydrolysate in bone and joint disease. Semin Arthritis Rheum. 2000;30(2):87–99.

    Article  PubMed  CAS  Google Scholar 

  54. Benito-Ruiz P, Camacho-Zambrano MM, Carrillo-Arcentales JN, et al. A randomized controlled trial on the efficacy and safety of a food ingredient, collagen hydrolysate, for improving joint comfort. Int J Food Sci Nutr. 2009;60(Suppl. 2):99–113.

    Article  PubMed  CAS  Google Scholar 

  55. Lequesne M, Maheu E, Cadet C, et al. Structural effect of avocado/soybean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Rheum. 2002;47(1):50–8.

    Article  PubMed  CAS  Google Scholar 

  56. Blotman F, Maheu E, Wulwik A, et al. Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip. A prospective, multicenter, three-month, randomized, double-blind, placebo-controlled trial. Rev Rhum Engl Ed 1997;64(12):825–34.

    Google Scholar 

  57. Maheu E, Mazieres B, Valat JP, et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip: a prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial with a six-month treatment period and a two-month followup demonstrating a persistent effect. Arthritis Rheum. 1998;41(1):81–91.

    Article  PubMed  CAS  Google Scholar 

  58. Appelboom T, Schuermans J, Verbruggen G, et al. Symptoms modifying effect of avocado/soybean unsaponifiables (ASU) in knee osteoarthritis. A double blind, prospective, placebo-controlled study. Scand J Rheumatol. 2001;30(4):242–7.

    Article  PubMed  CAS  Google Scholar 

  59. Maheu E, Cadet C, Marty M, et al. Evaluation of the structure modifying effects of the avacado-soybean unsaponifiables (ASU): results of the ERADUAS study, a 3-year prospective, randomized, double-vlind placebo controlled trial. Osteoarthr Cartil 2010; 18(S2):S45–S256.

    Google Scholar 

  60. Hochberg MC, Clegg DO. Potential effects of chondroitin sulfate on joint swelling: a GAIT report. Osteoarthr Cartil. 2008;16(Suppl. 3):S22–4.

    Article  PubMed  Google Scholar 

  61. Raynauld JP, Martel-Pelletier J, Berthiaume MJ, et al. Correlation between bone lesion changes and cartilage volume loss in patients with osteoarthritis of the knee as assessed by quantitative magnetic resonance imaging over a 24-month period. Ann Rheum Dis. 2008;67(5):683–8.

    Article  PubMed  Google Scholar 

  62. Raynauld JP, Martel-Pelletier J, Abram F, et al. Analysis of the precision and sensitivity to change of different approaches to assess cartilage loss by quantitative MRI in a longitudinal multicentre clinical trial in patients with knee osteoarthritis. Arthritis Res Ther. 2008;10(6):R129.

    Article  PubMed  Google Scholar 

  63. Pelletier JP, Raynauld JP, Abram F, et al. A new non-invasive method to assess synovitis severity in relation to symptoms and cartilage volume loss in knee osteoarthritis patients using MRI. Osteoarthr Cartil. 2008;16(Suppl. 3):S8–13.

    Article  PubMed  Google Scholar 

  64. Bioiberica. Study on the efficacy and safety of chondroitin sulfate and glucosamine hydrocloride versus celecoxib in knee osteoarthritis treatment (MOVES). 2011. http://clinicaltrials.gov/ct2/show/NCT01425853. Accessed 16 Nov 2011.

  65. Muller-Fassbender H, Bach GL, Haase W, et al. Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee. Osteoarthr Cartil. 1994;2(1):61–9.

    Article  PubMed  CAS  Google Scholar 

  66. Frestedt JL, Walsh M, Kuskowski MA, et al. A natural mineral supplement provides relief from knee osteoarthritis symptoms: a randomized controlled pilot trial. Nutr J. 2008;7:9.

    Article  PubMed  Google Scholar 

  67. Mehta K, Gala J, Bhasale S, et al. Comparison of glucosamine sulfate and a polyherbal supplement for the relief of osteoarthritis of the knee: a randomized controlled trial [ISRCTN25438351]. BMC Complement Altern Med. 2007;7:34.

    Article  PubMed  Google Scholar 

  68. Gruenwald J, Petzold E, Busch R, et al. Effect of glucosamine sulfate with or without omega-3 fatty acids in patients with osteoarthritis. Adv Ther. 2009;26(9):858–71.

    Article  PubMed  CAS  Google Scholar 

  69. Pavelka K, Coste P, Geher P, et al. Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clin Rheumatol. 2010;29(6):659–70.

    Article  PubMed  Google Scholar 

  70. Morreale P, Manopulo R, Galati M, et al. Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. J Rheumatol. 1996;23(8):1385–91.

    PubMed  CAS  Google Scholar 

  71. Kwoh CK, Roemer FW, Hannon MJ, et al. The joints on glucosamine (JOG) study: a randomized, double-blind, placebo-controlled trial to assess the dtructural benefit of glucosaine in knee osteoartritis based on 3T MRI [abstract]. Arthritis Rheum 2009;60(S10):1942.

    Google Scholar 

  72. University of Sydney. Long-term Evaluation of Glucosamine Sulfate Study (LEGS). 2010. http://clinicaltrials.gov/ct2/show/NCT00513422. (Accessed 16 Nov 2011).

  73. Cibere J, Kopec JA, Thorne A, et al. Randomized, double-blind, placebo-controlled glucosamine discontinuation trial in knee osteoarthritis. Arthritis Rheum. 2004;51(5):738–45.

    Article  PubMed  CAS  Google Scholar 

  74. Bruyere O, Pavelka K, Rovati LC, et al. Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarthr Cartil. 2008;16(2):254–60.

    Article  PubMed  CAS  Google Scholar 

  75. Aghazadeh-Habashi A, Jamali F. The glucosamine controversy: a pharmacokinetic issue. J Pharm Pharm Sci. 2011;14(2):264–73.

    PubMed  CAS  Google Scholar 

  76. Oesser S, Seifert J. Stimulation of type II collagen biosynthesis and secretion in bovine chondrocytes cultured with degraded collagen. Cell Tissue Res. 2003;311(3):393–9.

    PubMed  CAS  Google Scholar 

  77. McAlindon TE, Nuite M, Krishnan N, et al. Change in knee osteoarthritis cartilage detected by delayed gadolinium enhanced magnetic resonance imaging following treatment with collagen hydrolysate: a pilot randomized controlled trial. Osteoarthr Cartil. 2011;19(4):399–405.

    Article  PubMed  CAS  Google Scholar 

  78. Ernst E. Avocado-soybean unsaponifiables (ASU) for osteoarthritis: a systematic review. Clin Rheumatol. 2003;22(4–5):285–8.

    Article  PubMed  CAS  Google Scholar 

  79. Msika P, Baudouin C, Saunois A, et al. Avocado/soybean unsaponifiables, ASU EXPANSCIENCE, are strictly different from the nutraceutical products claiming ASU appellation. Osteoarthr Cartil. 2008;16(10):1275–6.

    Article  PubMed  CAS  Google Scholar 

  80. Henrotin YE, Labasse AH, Jaspar JM, et al. Effects of three avocado/soybean unsaponifiable mixtures on metalloproteinases, cytokines and prostaglandin E2 production by human articular chondrocytes. Clin Rheumatol. 1998;17(1):31–9.

    Article  PubMed  CAS  Google Scholar 

  81. Gabay O, Gosset M, Levy A, et al. Stress-induced signaling pathways in hyalin chondrocytes: inhibition by avocado-soybean unsaponifiables (ASU). Osteoarthr Cartil. 2008;16(3):373–84.

    Article  PubMed  CAS  Google Scholar 

  82. Henrotin YE, Deberg MA, Crielaard JM, et al. Avocado/soybean unsaponifiables prevent the inhibitory effect of osteoarthritic subchondral osteoblasts on aggrecan and type II collagen synthesis by chondrocytes. J Rheumatol. 2006;33(8):1668–78.

    PubMed  Google Scholar 

  83. Christensen R, Bartels EM, Astrup A, et al. Symptomatic efficacy of avocado-soybean unsaponifiables (ASU) in osteoarthritis (OA) patients: a meta-analysis of randomized controlled trials. Osteoarthr Cartil. 2008;16(4):399–408.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

No funding was used in the preparation of this manuscript. The author Ryan L. Ragle has no conflicts of interest relevant to this manuscript. Allen D. Sawitzke has served as a speaker and consultant for Bioiberica S.A., a manufacturer of chondroitin sulphate and its supplier for the GAIT and MOVES studies. In addition, he is the principal investigator on a biomarker in OA trial funded by Bioiberica S.A.

Author information

Authors and Affiliations

  1. School of Medicine, University of Utah, 30N 1900 E SOM 4B200, Salt Lake City, UT, 84132, USA

    Ryan L. Ragle & Allen D. Sawitzke

Authors
  1. Ryan L. Ragle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Allen D. Sawitzke
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ragle, R.L., Sawitzke, A.D. Nutraceuticals in the Management of Osteoarthritis. Drugs Aging 29, 717–731 (2012). https://doi.org/10.1007/s40266-012-0006-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-012-0006-3

Keywords

Search

Navigation